Correction/maintenance dosing (front loading) of darbepoetin alfa: Final results from a randomized phase III active-controlled trial

Journal of Supportive Oncology

Volumn 3, Issue 2 SUPPL. 1, 2005, Pages 16-17

  Kotasek, Dusan ^a   Canon, Jean Luc ^a   San Miguel, Jesus ^a   Hedenus, Michael ^a   Hendricks, Lisa ^a   Rossi, Greg ^a   Taylor, Kerry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 15944393118     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Kotasek D, Canon J-L, San Miguel J, et al. Correction/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized phase 3 active controlled trial. Poster presented at the 46th Annual Meeting of the American Society of Hematology; December 4-7, 2004; San Diego, Calif. Abstract 1636.